Literature DB >> 6435460

Lithium and tryptophan augmentation in clomipramine-resistant obsessive-compulsive disorder.

S A Rasmussen.   

Abstract

Obsessive-compulsive patients with symptoms resistant to clomipramine were treated by lithium or L-tryptophan augmentation. The improvement noted supports the hypothesis that increasing serotonergic neurotransmission ameliorates obsessive symptoms.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6435460     DOI： 10.1176/ajp.141.10.1283

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


  6 in total

1.  Obsessive Compulsive Disorder: Improving prognosis through therapy and drug treatment.

Authors:  V Goli; R Krishnan; E Ellinwood
Journal:  Can Fam Physician       Date:  1991-06       Impact factor: 3.275

Review 2.  A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.

Authors:  L L Carpenter; C J McDougle; C N Epperson; L H Price
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

Review 3.  Therapeutic approaches to the treatment of refractory obsessive-compulsive disorder.

Authors:  L D Kochan; A I Qureshi; B A Fallon
Journal:  Curr Psychiatry Rep       Date:  2000-08       Impact factor: 5.285

Review 4.  Current concepts in the pharmacological treatment of obsessive-compulsive disorder.

Authors:  J Zohar; R C Zohar-Kadouch; S Kindler
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

Review 5.  Eating disorder and obsessive-compulsive disorder: neurochemical and phenomenological commonalities.

Authors:  J L Jarry; F J Vaccarino
Journal:  J Psychiatry Neurosci       Date:  1996-01       Impact factor: 6.186

6.  Psychopharmacology of anxiety disorders.

Authors:  Giovanni B Cassano; Nicolò Baldini Rossi; Stefano Pini
Journal:  Dialogues Clin Neurosci       Date:  2002-09       Impact factor: 5.986
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.